Lyra Therapeutics (LYRA) Operating Income (2021 - 2025)
Historic Operating Income for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$6.2 million.
- Lyra Therapeutics' Operating Income rose 4987.14% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.3 million, marking a year-over-year increase of 6518.14%. This contributed to the annual value of -$96.3 million for FY2024, which is 4354.59% down from last year.
- Latest data reveals that Lyra Therapeutics reported Operating Income of -$6.2 million as of Q3 2025, which was up 4987.14% from -$8.8 million recorded in Q2 2025.
- In the past 5 years, Lyra Therapeutics' Operating Income ranged from a high of -$6.2 million in Q3 2025 and a low of -$49.0 million during Q2 2024
- Over the past 5 years, Lyra Therapeutics' median Operating Income value was -$13.6 million (recorded in 2021), while the average stood at -$15.1 million.
- As far as peak fluctuations go, Lyra Therapeutics' Operating Income plummeted by 19675.82% in 2024, and later skyrocketed by 8197.82% in 2025.
- Lyra Therapeutics' Operating Income (Quarter) stood at -$13.6 million in 2021, then dropped by 11.12% to -$15.2 million in 2022, then fell by 8.72% to -$16.5 million in 2023, then skyrocketed by 30.76% to -$11.4 million in 2024, then soared by 45.33% to -$6.2 million in 2025.
- Its Operating Income was -$6.2 million in Q3 2025, compared to -$8.8 million in Q2 2025 and -$8.8 million in Q1 2025.